EP
ATXS

Eversept Partners’s Astria Therapeutics ATXS Stock Holding History

Eversept Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-87,007
Closed -$1.12M – 88
2020
Q4 		$1.12M Buy
+87,007
New +$1.55M 0.13% 49

Other funds holding ATXS

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Eversept Partners's ATXS Position: Q1 2021 in Review

Eversept Partners sold out of Astria Therapeutics (ATXS) in Q1 2021, closing a stake of 87,007 shares — an estimated $1.12M sold.

Eversept Partners first reported a position in ATXS in Q4 2020 and held it in 1 quarter. The position peaked at $1.12M in Q4 2020. 61 funds tracked by Wall St. Rank hold ATXS as of Q1 2021.

  • Eversept Partners reported no remaining Astria Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Eversept Partners sold 87,007 Astria Therapeutics shares in Q1 2021, an estimated $1.12M.
  • Eversept Partners first reported a position in Astria Therapeutics in Q4 2020 and held it in 1 quarter.
  • Eversept Partners's Astria Therapeutics position peaked at $1.12M in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.